SCHEMBL3056569

SCHEMBL3056569

O=S(=O)(CCc1ccc(C(F)(F)F)c(Cl)c1)c1ccc(S(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.71

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 6/20 0.71
SCN9A Q15858 7/20 0.54
LMNA P02545 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
SCN5A Q14524 3/20 0.48
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP2C9 P11712 1/20 0.46
EDNRA P25101 1/20 0.46
SLC6A4 P31645 1/20 0.46
ADRA1A P35348 1/20 0.46
PRMT6 Q96LA8 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
SCN1A P35498 1/20 0.46
SCN8A Q9UQD0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3065484 0.92 SCN3A (0.71) SCN3ASCN9ALMNASMN1; SMN2SCN5A
SCHEMBL3061298 0.89 SCN3A (0.73) SCN3ASCN9ALMNASMN1; SMN2KDM4E
SCHEMBL3073689 0.87 SCN3A (0.73) SCN3ASCN9ALMNASMN1; SMN2KDM4E
SCHEMBL3060376 0.86 SCN3A (0.70) SCN3ASCN9ALMNASMN1; SMN2SCN5A
SCHEMBL3050819 0.84 SCN3A (0.58) SCN3ASCN9ASCN5ATDP1SCN1A
SCHEMBL3063891 0.84 SCN3A (0.65) SCN3ASCN9ALMNASMN1; SMN2SCN5A
SCHEMBL3055423 0.83 SCN3A (0.49) SCN3ASCN9ASCN5ACYP2C9SCN1A
SCHEMBL3060426 0.83 SCN3A (1.00) SCN3ASCN9ALMNASMN1; SMN2SCN5A
SCHEMBL3068460 0.82 SCN3A (0.77) SCN3ASCN9ALMNASMN1; SMN2SCN5A
SCHEMBL3129685 0.81 SCN3A (0.77) SCN3ASCN9ALMNASMN1; SMN2SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140357685-A1 Sodium Channel Inhibitors ICAGEN INC (US) 2014-12-04 US disclosed
US-8853250-B2 Sodium channel inhibitors ICAGEN, INC. (US) 2014-10-07 US disclosed
EP-2175728-B1 SODIUM CHANNEL INHIBITORS ICAGEN INC (US) 2014-09-10 EP disclosed
US-20100267782-A1 SODIUM CHANNEL INHIBITORS ICAGEN, INC (US) 2010-10-21 US disclosed
EP-2175728-A1 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-21 EP disclosed
WO-2009012241-A1 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357685-A1 Sodium Channel Inhibitors TRPV1, SCN1A, SCN2A SCN3A 8/4885SCN9A 19/4885LMNA 3041/4885
US-20100267782-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A SCN3A 8/4885SCN9A 19/4885LMNA 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.